FDA Approves Adcetris for Refractory Hodgkin’s Disease and a Rare T-Cell Lymphoma
Late Friday afternoon, the FDA announced its approval, upon accelerated review, of a new drug, Adcetris (brentuximab) for patients with Hodgkin’s lymphoma that has relapsed after bone marrow …
